<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003873.pub2" GROUP_ID="IBD" ID="532302041114390775" MERGED_FROM="" MODIFIED="2008-07-17 15:02:39 +0200" MODIFIED_BY="John MacDonald" REVIEW_NO="43" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-07-17 15:02:39 +0200" MODIFIED_BY="John MacDonald">
<TITLE>Interventions for growth failure in childhood Crohn's disease</TITLE>
<CONTACT MODIFIED="2008-07-17 15:02:39 +0200" MODIFIED_BY="John MacDonald"><PERSON ID="37FFD73082E26AA201071537F11AD818" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Adrian G</FIRST_NAME><LAST_NAME>Thomas</LAST_NAME><POSITION>Consultant Paediatric Gastroenterologist</POSITION><EMAIL_1>adrian.thomas@cmmc.nhs.uk</EMAIL_1><ADDRESS><ORGANISATION>Booth Hall Childrens Hospital</ORGANISATION><ADDRESS_1>Charlestown Road</ADDRESS_1><ADDRESS_2>Blackley</ADDRESS_2><CITY>Manchester</CITY><ZIP>M9 7AA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 918 5566</PHONE_1><PHONE_2>+44 161 918 5458 </PHONE_2><FAX_1>+ 44 161 918 5072</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-07-17 15:02:39 +0200" MODIFIED_BY="John MacDonald"><PERSON ID="18647" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elizabeth</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Newby</LAST_NAME><POSITION>Specialist Registrar Paediatrics</POSITION><EMAIL_1>lizzy.newby@virgin.net</EMAIL_1><ADDRESS><ORGANISATION>Alder Hey Children's Hospital</ORGANISATION><ADDRESS_1>Eaton Road</ADDRESS_1><CITY>Liverpool</CITY><ZIP>L12 2AP</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="18649" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A</FIRST_NAME><LAST_NAME>Sawczenko</LAST_NAME><EMAIL_1>a.s@i.am</EMAIL_1><ADDRESS><DEPARTMENT>Department of Gastroenterology</DEPARTMENT><ORGANISATION>Bristol Children's Hospital</ORGANISATION><ADDRESS_1>Upper Maudlin Street</ADDRESS_1><CITY>Bristol</CITY><ZIP>BS2 8BJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="37FFD73082E26AA201071537F11AD818" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Adrian G</FIRST_NAME><LAST_NAME>Thomas</LAST_NAME><POSITION>Consultant Paediatric Gastroenterologist</POSITION><EMAIL_1>adrian.thomas@cmmc.nhs.uk</EMAIL_1><ADDRESS><ORGANISATION>Booth Hall Childrens Hospital</ORGANISATION><ADDRESS_1>Charlestown Road</ADDRESS_1><ADDRESS_2>Blackley</ADDRESS_2><CITY>Manchester</CITY><ZIP>M9 7AA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 918 5566</PHONE_1><PHONE_2>+44 161 918 5458 </PHONE_2><FAX_1>+ 44 161 918 5072</FAX_1></ADDRESS></PERSON><PERSON ID="8317" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Wilson</LAST_NAME><POSITION>Senior Lecturer in Paediatric Gastroenterology and Nutrition</POSITION><EMAIL_1>d.c.wilson@ed.ac.uk</EMAIL_1><ADDRESS><ORGANISATION>Edinburgh Sick Children's NHS Trust</ORGANISATION><ADDRESS_1>Royal Hospital for Sick Children</ADDRESS_1><ADDRESS_2>Sciennes Road</ADDRESS_2><CITY>Edinburgh</CITY><ZIP>EH9 1LF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 131 536 0690</PHONE_1><FAX_1>+44 131 536 0821</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-07-17 08:40:11 -0400" MODIFIED_BY="John MacDonald">
<UP_TO_DATE>
<DATE DAY="16" MONTH="5" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="5" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="6" YEAR="2007"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2005"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="17" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="16" MONTH="5" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-07-17 08:56:17 -0400" MODIFIED_BY="John K MacDonald">
<SUMMARY>
<TITLE>Interventions for growth failure in childhood Crohn's disease</TITLE>
<SUMMARY_BODY>
<P>Growth failure occurs in 15-40% of children with Crohn's disease. Growth in affected children is influenced by the disease process itself and by some treatments. Management in children differs from that in adults because of the required emphasis on achieving optimum growth and pubertal development. The aim of this review was to evaluate the effectiveness of various treatments for growth failure in childhood Crohn's disease. Three randomized controlled trials were identified. One trial did not show any benefit for linear growth with 6-mercaptopurine treatment compared to placebo among children being treated with steroids. The other two trials looked at nutritional treatment (elemental feedings) versus steroids (prednisolone). Both trials showed a statistically significant benefit for height velocity standard deviation scores with nutritional treatment. However, these results need to be confirmed by large, multi-centre, randomized controlled trials of therapeutic interventions in pre-pubertal children with Crohn's disease. These trials should use growth as an outcome measure. In conclusion, more research is needed to identify effective treatments for growth failure in childhood Crohn's disease.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Crohn's disease in childhood is a chronic relapsing condition. Fifteen to forty per cent of children with Crohn's disease have growth retardation (Griffiths 1993a). Some treatment modalities including corticosteroids have been implicated in growth failure but it is thought mainly to be secondary to uncontrolled disease activity (Motil 1993; Markowitz 1993). Growth is fundamental to the practice of pediatrics, so by taking growth as the primary outcome measure we address issues important to both patients, their families and pediatricians.<BR/> </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effectiveness of the different modalities available for the treatment of childhood Crohn's disease with regard to the reversal of growth failure and the promotion of normal growth. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Searches were made of the following databases using the Collaborative Review Group Search Strategy: EMBASE (1984-2004), MEDLINE (1966-2004), The Cochrane Central Register of Controlled Trials, The Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group Specialized Trials Register and the Science Citation Index. Abstracts from the major gastrointestinal research meetings and references from published articles were also reviewed. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized controlled trials pertaining to children less than 18 years of age with Crohn's disease were selected. Those with growth as an outcome measure were included in the review.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data extraction and assessment of the methodological quality of each trial was independently reviewed by two reviewers. Only one good quality randomized controlled trial was included in the review and therefore no statistical analysis was possible.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Three randomized controlled trials were identified. One was of good methodological quality (Markowitz 2000). This study looked at the use of 6-mercaptopurine (6-MP) as a steroid sparing agent. No difference in linear growth was observed between the intervention and placebo groups, although the total steroid dose received over the 18 month follow up period was reduced in the group receiving 6-MP. The two remaining randomized controlled trials (Sanderson 1987; Thomas 1993a) consider the use of enteral feeding versus corticosteroids for induction of remission, with height velocity standard deviation score at 6 months as an outcome measure. Although of less rigorous methodological quality, the results of these studies are discussed in detail in the review. In both studies height velocity standard deviation scores were significantly increased in the enteral feeding group compared with the corticosteroid group.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>In addition to these randomized controlled trials, a body of lower quality evidence does exist relevant to two other important interventions; the use of supplemental enteral nutrition (Morin 1980; Belli 1988; Israel 1995) and the judicious use of surgical interventions in pre-pubertal children with refractory disease (Alperstein 1985; Lipson 1990; McLain 1990). Newer treatments, such as infliximab, are now becoming more widely used and may offer advantages in promoting growth. These effects are as yet unstudied. This review highlights the need for large, multi centre studies of the different treatment options in paediatric Crohn's disease and the importance of standardised measurements of growth, such as height velocity standard deviation scores and height standard deviation scores as outcome measures.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-17 08:56:17 -0400" MODIFIED_BY="John K MacDonald">
<BACKGROUND MODIFIED="2008-07-17 08:56:17 -0400" MODIFIED_BY="John K MacDonald">
<P>Crohn's disease in childhood is a chronic relapsing condition for which growth is an important measure of disease severity and can be used to monitor the success of medical treatments and nutritional or surgical interventions. Growth is fundamental to the practice of pediatrics, so by taking growth as the primary outcome we address core issues that are important to, both patients, their families and pediatricians.</P>
<P>Growth failure affects 15-40% of children with Crohn's disease (<LINK REF="REF-Griffiths-1993a" TYPE="REFERENCE">Griffiths 1993a</LINK>; <LINK REF="STD-Motil-1993" TYPE="STUDY">Motil 1993</LINK>). Variation in the reported prevalence of growth failure may be due to the study population (population based versus tertiary referral centre), definition of growth failure and age of children included in study. One small study showed these children did achieve normal adult height (<LINK REF="REF-Ferguson-1994" TYPE="REFERENCE">Ferguson 1994</LINK>) but other work has suggested that up to 25% of patients will ultimately not achieve their full adult growth potential (<LINK REF="REF-Hildebrand-1994" TYPE="REFERENCE">Hildebrand 1994</LINK>; <LINK REF="REF-Buller-2000" TYPE="REFERENCE">Buller 2000</LINK>). Growth failure is at least twice as common in Crohn's disease compared to ulcerative colitis. This is most likely to be a consequence of the disease process rather than the unwanted effects of therapy (<LINK REF="REF-Markowitz-1993" TYPE="REFERENCE">Markowitz 1993</LINK>; <LINK REF="STD-Motil-1993" TYPE="STUDY">Motil 1993</LINK>).</P>
<P>Poor nutrition and malabsorption were thought to be the major causes of growth failure in Crohn's disease. We know from earlier work that children with active Crohn's disease have low serum insulin-like growth factor I (IGF-I) levels. IGF-I is a polypeptide which acts as a stimulus to growth by mediating the anabolic effects of growth hormone. However, levels of growth hormone itself are not suppressed (<LINK REF="STD-Thomas-1993b" TYPE="STUDY">Thomas 1993b</LINK>; <LINK REF="STD-Akobeng-2002" TYPE="STUDY">Akobeng 2002</LINK>; <LINK REF="REF-Beattie-1998" TYPE="REFERENCE">Beattie 1998</LINK>; <LINK REF="REF-Kirschner-1986" TYPE="REFERENCE">Kirschner 1986</LINK>). There is now evidence that the inflammatory process itself is also responsible for poor growth via direct suppression of IGF-I at the hepatocyte level. Inflammatory cytokines, such as tumour necrosis factor-&#945; (TNF-&#945;) and interleukin-6 (IL-6) are increased in Crohn's disease and have been shown to suppress IGF-I concentrations in animal models allowing for the confounding effect of nutrition (<LINK REF="REF-Murch-1991" TYPE="REFERENCE">Murch 1991</LINK>; <LINK REF="REF-De-Benedetti-1997" TYPE="REFERENCE">De Benedetti 1997</LINK>; <LINK REF="REF-Ballinger-2000" TYPE="REFERENCE">Ballinger 2000</LINK>). Treatments aimed at reversing growth failure need to address nutrition and also target the underlying inflammatory process.</P>
<P>Definitions of growth failure often used include: "height below the third percentile", "velocity of linear growth and of weight gain below the third percentile", "bone age retarded by 2 years" (<LINK REF="STD-Belli-1988" TYPE="STUDY">Belli 1988</LINK>) and "height velocity less than third percentile for age and bone age greater than 2 standard deviations below chronological age" (<LINK REF="STD-Polk-1992" TYPE="STUDY">Polk 1992</LINK>) and "no signs of puberty" (<LINK REF="STD-Morin-1980" TYPE="STUDY">Morin 1980</LINK>). Outcome measures of growth can also vary between studies, with some papers comparing change in height standard deviation score (SDS) or Z score, whilst others look at change in height velocity. Pubertal staging of children is also very important as declining height velocities may be a reflection of post-pubertal status and not disease activity. Any intervention to reverse growth failure should be initiated well before completion of puberty. Tanner staging (1-5) should be quoted for all children included in any analysis of growth failure (<LINK REF="REF-Walker_x002d_Smith-1996" TYPE="REFERENCE">Walker-Smith 1996</LINK>).</P>
<P>Quality of life issues are becoming increasingly recognized as important outcome measures (<LINK REF="REF-Akobeng-1999" TYPE="REFERENCE">Akobeng 1999</LINK>). In pediatrics, growth is integral to quality of life as growth failure and developmental delay can have devastating psychological consequences for children. This is especially pertinent to adolescents who make up a large percentage of pediatric Crohn's disease patients. </P>
<P>The need to promote growth and development has long been recognised in pediatric Crohn's disease and many studies have looked at growth as an outcome measure, albeit as a secondary outcome. Many therapies have been shown to be effective in reducing inflammatory markers, symptomatology or the Pediatric Crohn's Disease Activity Index (<LINK REF="REF-Hyams-1991" TYPE="REFERENCE">Hyams 1991</LINK>) with variable effectiveness on reversal of growth failure. </P>
<P>Potential interventions</P>
<P>Medical interventions:</P>
<P>One of the main stays of medical treatment for Crohn's disease has been the use of corticosteroids, the adverse effects of which include inhibition of growth. Studies on the use of steroids have commented on this undesirable effect whilst also commenting on their efficacy in lowering disease activity. However, growth suppression secondary to sub-optimal control of disease may be more important for growth failure than the adverse effects of corticosteroid usage (<LINK REF="STD-Motil-1993" TYPE="STUDY">Motil 1993</LINK>). </P>
<P>Traditionally, the use of the immunosuppressive azathioprine and it's analogues, 6-mercaptopurine and thioguanine, has been reserved for severe refractory disease but more recent studies have shown early azathioprine usage can prevent relapse and can be used as a steroid sparing agent (<LINK REF="STD-Markowitz-2000" TYPE="STUDY">Markowitz 2000</LINK>). Pooled adult data provides an odds ratio of 2.16 (95% CI 1.35 - 3.47) for maintenance of remission with azathioprine (<LINK REF="REF-Pearson-1998" TYPE="REFERENCE">Pearson 1998</LINK>). Theoretically, a longer period of remission combined with decreased steroid use should have a beneficial effect on growth, although this has not been prospectively studied. <LINK REF="STD-Markowitz-2000" TYPE="STUDY">Markowitz 2000</LINK> did demonstrate a steroid sparing effect in a pediatric population, with significant improvement in the rate of remission. However, linear growth did not differ over the follow-up period.</P>
<P>5-ASA compounds are widely used in maintenance therapy in Crohn's disease but with little evidence supporting their use (<LINK REF="REF-Akobeng-2005" TYPE="REFERENCE">Akobeng 2005</LINK>). There is much stronger evidence for their efficacy in ulcerative colitis (<LINK REF="REF-Sutherland-2006" TYPE="REFERENCE">Sutherland 2006</LINK>). Their role in promotion of growth is, therefore, probably negligible (<LINK REF="STD-Griffiths-1993b" TYPE="STUDY">Griffiths 1993b</LINK>).</P>
<P>A variety of immuno modulating agents such as cyclosporine A, tacrolimus, infliximab, mycophenolate, methotrexate and thalidomide are currently in use in childhood Crohn's disease. Their use has usually been confined to patients with refractory disease.<BR/> <BR/>More recently, the use of infliximab, a chimeric monoclonal antibody to TNF-&#945; has become accepted practice in the management of refractory disease. Studies have shown good efficacy although more long term follow-up data are not yet available (<LINK REF="REF-Hyams-2000" TYPE="REFERENCE">Hyams 2000</LINK>; <LINK REF="STD-Kugathasan-2000" TYPE="STUDY">Kugathasan 2000</LINK>; <LINK REF="REF-Stephens-2003" TYPE="REFERENCE">Stephens 2003</LINK>; <LINK REF="STD-Baldassano-2003" TYPE="STUDY">Baldassano 2003</LINK>). Small amounts of growth data are now emerging with encouraging results (<LINK REF="STD-Cezard-2003" TYPE="STUDY">Cezard 2003</LINK>).<BR/> <BR/>Nutritional interventions:</P>
<P>There has been much work on the role of enteral nutrition for the treatment of Crohn's disease in children. There have been a number of small studies which, although being underpowered to detect a difference in efficacy in acute disease compared with corticosteroids, do cite the added benefit of growth promotion (<LINK REF="STD-Sanderson-1987" TYPE="STUDY">Sanderson 1987</LINK>; <LINK REF="STD-Thomas-1993a" TYPE="STUDY">Thomas 1993a</LINK>; <LINK REF="STD-Papadopoulou-1995" TYPE="STUDY">Papadopoulou 1995</LINK>). A recent meta-analysis shows that enteral nutrition is less likely than corticosteroids to induce remission with a pooled odds ratio of 0.31 (95% CI 0.17 - 0.52), although these data are mainly from studies in adults (<LINK REF="REF-Zachos-2007" TYPE="REFERENCE">Zachos 2007</LINK>). Enteral feeding has also been shown to improve growth in Crohn's disease after remission has been induced (<LINK REF="STD-Belli-1988" TYPE="STUDY">Belli 1988</LINK>; <LINK REF="STD-Wilschanski-1996" TYPE="STUDY">Wilschanski 1996</LINK>). In the case of non-acceptance of enteral feeding, administration of parenteral nutrition has been shown to be effective in improving nutrition and growth (<LINK REF="REF-Keller-1992" TYPE="REFERENCE">Keller 1992</LINK>; <LINK REF="STD-Strobel-1979" TYPE="STUDY">Strobel 1979</LINK>).</P>
<P>Hormonal Interventions</P>
<P>Growth Hormone:</P>
<P>Interest in growth hormone as a possible treatment for Crohn's disease in childhood has been generated by work with adult patients. <LINK REF="REF-Slonim-2000" TYPE="REFERENCE">Slonim 2000</LINK> randomized patients to receive growth hormone or placebo over a 16-week course, with a significant improvement in the Crohn's disease activity index seen in the intervention group. The mechanism of action is thought to be enhancement of the benefit of supplemental protein on the gut by increase in the uptake of amino acids and electrolytes, decrease in intestinal permeability and increased protein synthesis.</P>
<P>Testosterone:</P>
<P>Testosterone has been used by some in boys where there is extreme delay in puberty, although there are no randomized clinical trials of this intervention (<LINK REF="REF-Walker_x002d_Smith-1996" TYPE="REFERENCE">Walker-Smith 1996</LINK>).</P>
<P>Surgical interventions:</P>
<P>Correct timing of surgical interventions can also have extremely important consequences for growth promotion and pubertal development (<LINK REF="STD-Alperstein-1985" TYPE="STUDY">Alperstein 1985</LINK>; <LINK REF="STD-Davies-1990" TYPE="STUDY">Davies 1990</LINK>; <LINK REF="REF-Evans-1991" TYPE="REFERENCE">Evans 1991</LINK>; <LINK REF="REF-Griffiths-1991" TYPE="REFERENCE">Griffiths 1991</LINK>). </P>
<P>Although growth failure is common in pediatric Crohn's disease and many studies have commented on potential benefits of therapy on growth this approach does not appear to have been reviewed systematically. The aim of this review is to examine the evidence from randomized controlled trials of medical, nutritional and surgical interventions for the treatment of growth failure in childhood Crohn's disease.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effectiveness of the different modalities for the treatment of growth failure and the promotion of normal growth in childhood Crohn's disease. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomized controlled trials of any medical, nutritional or surgical intervention in childhood Crohn's disease with growth as a primary or secondary outcome measure. Studies published as abstracts only were excluded from the analysis.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients aged less than 18 years with Crohn's disease.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any recognized medical, nutritional or surgical intervention in Crohn's disease in children.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The reversal of growth failure at any point in the course of the disease process. Growth failure will be as defined by the authors provided one of the previously mentioned definitions is applied or other appropriately used definitions are given. Reversal of growth failure will be defined as a return to normal height velocity or exhibition of catch-up growth.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See: Collaborative Review Group Search Strategy</P>
<P>A. Electronic searching<BR/>The following electronic databases were searched for relevant studies:<BR/>1. EMBASE (1984-2004) <BR/>2. MEDLINE (1966-2004) <BR/>3. The Cochrane Central Register of Controlled Trials <BR/>4. The Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group Specialized Trials Register<BR/>5. Science Citation Index</P>
<P>EMBASE and MEDLINE on OVID were searched using the following search strategy:<BR/>#1 randomized controlled trial.pt<BR/>#2 controlled clinical trial.pt<BR/>#3 clinical trial.pt<BR/>#4 research design<BR/>#5 explode "Randomized-Controlled-Trial/all subheadings"<BR/>#6 explode "Random-Allocation/all subheadings"<BR/>#7 explode "Double-Blind-Method/all subheadings"<BR/>#8 explode "Single-Blind-Method/all subheadings"<BR/>#9 explode "clinical-trial/all subheadings"<BR/>#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9<BR/>#11 placebo$<BR/>#12 placebo$.ti<BR/>#13 placebo$.ab<BR/>#14 random$<BR/>#15 random$.ti<BR/>#16 random$.ab<BR/>#17 volunteer$<BR/>#18 volunteer$.ti<BR/>#19 volunteer$.ab<BR/>#20 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19<BR/>#21 singl$ or doubl$ or trebl$ or tripl$<BR/>#22 blind$ or mask$<BR/>#23 #21 or #22 <BR/>#24 #21 and #22<BR/>#25 #10 or #20 or #24<BR/>#26 Limit #25 to human<BR/>#27 inflammatory bowel disease.ti<BR/>#28 inflammatory bowel disease.ab<BR/>#29 inflammatory bowel disease.tw<BR/>#30 explode "Inflammatory-Bowel-Disease/all subheadings"<BR/>#31 crohn$.ti<BR/>#32 crohn$.ab<BR/>#33 crohn$.tw<BR/>#34 explode "Crohn-Disease/all subheadings"<BR/>#35 explode "Colitis-Ulcerative/all subheadings"<BR/>#36 colitis not ischaemic<BR/>#37 colitis not infectious<BR/>#38 #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37<BR/>#39 #26 and #38<BR/>#40 Limit #39 to ((age=adolescent) or (age=child) or (age=child-preschool) or (age=infant) or (age=infant-newborn)) <BR/>#41 growth<BR/>#42 explode "Growth-/all subheadings or Growth-Disorders/all subheadings"<BR/>#43 height<BR/>#44 explode "Body-Height/all subheadings"<BR/>#45 weight<BR/>#46 explode "Body-Weight/all subheadings"<BR/>#47 short$<BR/>#48 "short stature"<BR/>#49 thrive<BR/>#50 failure to thrive<BR/>#51 explode "Failure-To-Thrive/all subheadings"<BR/>#52 stunt$<BR/>#53 nutrit$<BR/>#54 explode "Nutrition-/all subheadings or Nutrition-Disorders/all subheadings or Enteral-Nutrition/all subheadings or Parenteral-Nutrition/all subheadings or Parenteral-Nutrition-Total/all subheadings"<BR/>#55 #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #55 or #51 or #52 or #53 or #54<BR/>#56 #40 and #55</P>
<P>Similar search strategies, modified appropriately, were used to search the other electronic databases listed above.</P>
<P>B. Reference Searching<BR/>The references of all identified studies were inspected for further randomized controlled trials.</P>
<P>C. Meeting Abstracts<BR/>A manual search of abstracts presented at major gastroenterology meetings and published in the following journals between 1990 and 2004 was performed to identify unpublished studies:<BR/>1. Gastroenterology (American Gastroenterological Association);<BR/>2. American Journal of Gastroenterology (American College of Gastroenterology);<BR/>3. Canadian Journal of Gastroenterology (Canadian Association of Gastroenterology);<BR/>4. Journal of Pediatric Gastroenterology and Nutrition (European Society of Paediatric Gastroenterology, Hepatology and Nutrition), (North American Society of Pediatric Gastroenterology, and Nutrition);<BR/>5. Gut (British Society of Gastroenterology);<BR/>6. and the Scandinavian Journal of Gastroenterology, (Nordic Gastroenterology meetings).</P>
<P>D. Personal Contacts<BR/>Leaders in the field were contacted to identify other studies.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>A. Selection of Trials<BR/>Two reviewers independently assessed identified studies for fulfillment of the inclusion criteria detailed above. Disagreement was resolved by consensus.</P>
<P>B. Quality Assessment<BR/>The methodological quality of included studies was independently assessed by two reviewers using: the scheme recommended in the Cochrane Reviewers' Handbook (<LINK REF="REF-Clarke-2003" TYPE="REFERENCE">Clarke 2003</LINK>) and the Jadad Scale (<LINK REF="REF-Jadad-1998" TYPE="REFERENCE">Jadad 1998</LINK>). Studies were included if they met the Cochrane Reviewers' Handbook criteria A or B and scored at least 2 points on the Jadad Scale.</P>
<P>C. Statistical Analysis<BR/>No statistical meta-analysis of pooled data was performed in this review as only one study of sufficient quality was identified. If in future any further randomized controlled trials are published, which meet the above criteria, the data will be analysed according to the intention-to-treat principal using the Cochrane Collaboration Review Manager software (RevMan version 4.2).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>The above search strategy produced 180 non-duplicated hits. Forty-one papers were fully reviewed as they concerned either growth or nutrition or were randomized controlled trials of treatment effect. Of the 41 studies reviewed, 3 were randomized controlled trials with growth as an outcome measure (<LINK REF="STD-Sanderson-1987" TYPE="STUDY">Sanderson 1987</LINK>; <LINK REF="STD-Thomas-1993a" TYPE="STUDY">Thomas 1993a</LINK>; <LINK REF="STD-Markowitz-2000" TYPE="STUDY">Markowitz 2000</LINK>). One study was a good quality randomized controlled trial (<LINK REF="STD-Markowitz-2000" TYPE="STUDY">Markowitz 2000</LINK>) and was included in the review. Two were not of rigorous methodological quality but are included and discussed below because they are highly relevant to the subject (<LINK REF="STD-Sanderson-1987" TYPE="STUDY">Sanderson 1987</LINK>; <LINK REF="STD-Thomas-1993a" TYPE="STUDY">Thomas 1993a</LINK>). In view of these methodological flaws, a pooled statistical analysis was not undertaken.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>In the <LINK REF="STD-Markowitz-2000" TYPE="STUDY">Markowitz 2000</LINK> study allocation of participants to intervention or placebo was random, i.e. by the use of permuted blocks. The trial was double-blinded and allocation concealment was adequate (A). The <LINK REF="STD-Markowitz-2000" TYPE="STUDY">Markowitz 2000</LINK> study was given a score of 4 on the Jadad scale. <LINK REF="STD-Sanderson-1987" TYPE="STUDY">Sanderson 1987</LINK> and <LINK REF="STD-Thomas-1993a" TYPE="STUDY">Thomas 1993a</LINK> did not discuss the randomization process or allocation concealment (D). The authors were contacted for additional information and both studies employed appropriate methods for the randomization of patients. Both <LINK REF="STD-Sanderson-1987" TYPE="STUDY">Sanderson 1987</LINK> and <LINK REF="STD-Thomas-1993a" TYPE="STUDY">Thomas 1993a</LINK> received a Jadad scale score of 2.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<LINK REF="STD-Markowitz-2000" TYPE="STUDY">Markowitz 2000</LINK> randomized 55 children ages 13 +/- 2 years with active Crohn's disease to receive prednisone 40 mg/day plus 6-mercaptopurine (6-MP) 1.5 mg/kg/day (n = 27) or prednisone 40 mg/day and placebo (n = 28). The 6-MP dose remained unchanged for 18 months whilst the prednisone dose varied in each group according to a standardised dosing regimen depending on disease activity. The two groups were comparable in terms of age, sex, sites of disease, disease activity and enrollment (early versus late). The study was analysed on an intention-to-treat basis. The 6-MP group required significantly less steroids during the study period (p &lt; 0.01), with significant improvement in days in remission (p &lt; 0.01) on survival analysis. Linear growth did not differ between the two groups at the end of the 18-month study period or at 6 month intervals within this time. At 18 months the mean and standard deviation for linear growth in the intervention group was 6.8 cm (4.1) compared with 5.3 cm (4.0) in the placebo group (p = 0.3). However, pubertal status was not taken into account in the analysis nor were the results compared with normal growth velocities.</P>
<P>
<LINK REF="STD-Thomas-1993a" TYPE="STUDY">Thomas 1993a</LINK> randomized 24 children aged less than 18 years with active Crohn's disease to receive normal diet, prednisolone 2 mg/kg/day for 2 weeks (maximum 60 mg/day), with subsequent dosage tapering depending on clinical response plus sulphasalazine 25 mg/kg or exclusive elemental feed for 4 weeks after which time normal diet was reintroduced as per a specified regimen. Twelve children were randomized to each group using sealed envelopes drawn from a box (author contacted). The characteristics (i.e. age, sex, height, weight, stunted, and wasted) of the 2 groups were compared but no comment made as to any statistically significant differences between them. Height was measured before commencing treatment and after 6 months. Height velocity standard deviation scores were calculated. The mean height velocity standard deviation score at 6 months in the enteral nutrition group was +0.32 (standard deviation = 3.32) compared with -3.1 (standard deviation = 2.8) in the steroid group (p &lt; 0.05). No comment on pubertal status was made. Improvement in disease activity (increase in Lloyd-Still activity index) and duration of remission was similar in the two groups. The drop-out rate was not discussed in this paper so no comment can be made as to whether the study was analysed on an intention-to-treat basis.</P>
<P>
<LINK REF="STD-Sanderson-1987" TYPE="STUDY">Sanderson 1987</LINK> randomized 17 children aged less than 18 years with active Crohn's disease to receive either normal diet, high dose steroids, i.e. 2 IU/kg/day intra-muscular adrenocorticotrophic hormone for 5 days followed by prednisolone 2 mg/kg/day (maximum 30 mg/day) with a reducing regimen instituted after 3 weeks plus sulphasalazine 50 mg/kg/day (n = 8) or exclusive elemental feed for 6 weeks then a food reintroduction programme over 6 weeks with elemental feed being stopped completely at the end of this 12 week period (n = 9). Randomization took place by a series of sealed envelopes marked 1-20 which were opened as the next patient was diagnosed and entered into the study. The treatment allocation to each envelope was randomly generated by the researcher at the start of the study (author contacted). The characteristics (i.e. age, sex, pubertal state, disease activity, height standard deviation score, ESR, and C reactive protein or albumin concentrations) of the 2 groups at entry into the trial were statistically comparable. Two children did not complete the trial, one from each group. Height was measured on entry to the study and at 6 months. Height velocity standard deviation scores were calculated. The mean height standard deviation score at 6 months was +0.3 (standard deviation = 2.03) in the enteral nutrition group and -2.8 (standard deviation = 2.50) in the steroid group (p &lt; 0.05). Results were not analysed on an intention-to-treat basis. In both groups the disease activity index (Lloyd-Still disease activity index) was significantly improved at 6 weeks <BR/>(p &lt; 0.01), with improvement of a similar magnitude being seen in both groups. Remission was maintained in both groups at 12 weeks at which time the enteral feed group were off treatment whereas the corticosteroid group remained on prednisolone (10 mg/kg/day). <LINK REF="STD-Sanderson-1987" TYPE="STUDY">Sanderson 1987</LINK> comments that there may be confounding factors in the data such as pubertal status, disease activity, steroid dosage and energy intake.</P>
<P>In both the <LINK REF="STD-Sanderson-1987" TYPE="STUDY">Sanderson 1987</LINK> and <LINK REF="STD-Thomas-1993a" TYPE="STUDY">Thomas 1993a</LINK> studies it was not possible to blind the researcher or participants to the interventions or the outcome measures because of their nature. <LINK REF="STD-Sanderson-1987" TYPE="STUDY">Sanderson 1987</LINK> and <LINK REF="STD-Thomas-1993a" TYPE="STUDY">Thomas 1993a</LINK> used different dosage schedules for steroids and regimens for length of course of enteral feeds.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Although only the three randomized controlled trials discussed above were identified, there are other data pertaining to growth in Crohn's disease which can be extracted from cohort and case control studies.</P>
<P>Enteral Nutrition</P>
<P>A recent meta-analysis (<LINK REF="REF-Heuschkel--2000" TYPE="REFERENCE">Heuschkel 2000</LINK>) looking at corticosteroids versus enteral nutrition for the treatment of acute Crohn's disease in children noted the statistically significant benefit of enteral nutrition for height velocity standard deviation scores. This outcome measure was not included in the meta-analysis because of the small number of children randomized. The studies included in the meta-analysis were of less rigorous methodological quality, mainly the studies addressed above (<LINK REF="STD-Sanderson-1987" TYPE="STUDY">Sanderson 1987</LINK>; <LINK REF="STD-Thomas-1993a" TYPE="STUDY">Thomas 1993a</LINK>) plus data from two abstracts (<LINK REF="REF-Seidman-1991" TYPE="REFERENCE">Seidman 1991</LINK>; <LINK REF="REF-Seidman-1993" TYPE="REFERENCE">Seidman 1993</LINK>) and a study with weight as the only outcome measure (<LINK REF="STD-Ruuska-1994" TYPE="STUDY">Ruuska 1994</LINK>). Two non-randomized trials were also included in the analysis (<LINK REF="REF-Breese-1994" TYPE="REFERENCE">Breese 1994</LINK>; <LINK REF="REF-Chafai-1995" TYPE="REFERENCE">Chafai 1995</LINK>).</P>
<P>One other randomized controlled trial looking at cycles of enteral nutrition versus alternate day steroids has been published in abstract form (<LINK REF="STD-Seidman-1996" TYPE="STUDY">Seidman 1996</LINK>). This study randomized 18 children to receive exclusive enteral nutrition for 4 weeks out of every 20 weeks over an 80 week study period with 19 children randomized to receive alternate day steroids (0.33 mg/kg qid). Relapse rates were improved in the enteral feed group, although this difference was not statistically significant. However, height standard deviation score was significantly improved in the enteral feed group (0.40+/-0.14 compared with -0.02+/-0.09; p = 0.02).</P>
<P>
<LINK REF="STD-Papadopoulou-1995" TYPE="STUDY">Papadopoulou 1995</LINK> retrospectively reviewed data on 28 children with an acute flare of Crohn's disease treated with corticosteroids using the same regimen as <LINK REF="STD-Thomas-1993a" TYPE="STUDY">Thomas 1993a</LINK> compared to 30 children treated with enteral nutrition. At 1 year the mean height standard deviation score for the steroid group was -0.13 compared with +0.85 for the enteral nutrition group (p &lt; 0.001).</P>
<P>Several cohort studies and case reports have looked at the value of longer term supplementary enteral nutrition as a means of promoting growth in Crohn's disease with up to 2 years of follow up data. After 1 year <LINK REF="STD-Polk-1992" TYPE="STUDY">Polk 1992</LINK> and <LINK REF="STD-Wilschanski-1996" TYPE="STUDY">Wilschanski 1996</LINK> showed significantly improved height velocities (p &lt; 0.001 in both studies) for a combined group of 30 children with Crohn's disease receiving supplemental enteral nutrition compared with those receiving standard medical therapy. <LINK REF="STD-Belli-1988" TYPE="STUDY">Belli 1988</LINK>, <LINK REF="STD-Israel-1995" TYPE="STUDY">Israel 1995</LINK> and <LINK REF="STD-Morin-1980" TYPE="STUDY">Morin 1980</LINK> showed improved growth in case reports of children receiving long term enteral nutrition. <LINK REF="REF-Cosgrove-1997" TYPE="REFERENCE">Cosgrove 1997</LINK> and <LINK REF="STD-Israel-1995" TYPE="STUDY">Israel 1995</LINK> also reported the advantages of gastrostomy placement in combination with supplemental feeding in childhood Crohn's disease. </P>
<P>Two types of enteral feed are available: elemental and polymeric. In a recent randomized controlled trial <LINK REF="STD-Ludvigsson-2004" TYPE="STUDY">Ludvigsson 2004</LINK> found no difference in efficacy for induction of remission between the two enteral feeds, but a slight advantage with polymeric feed with respect to weight gain. Height was not studied (<LINK REF="STD-Ludvigsson-2004" TYPE="STUDY">Ludvigsson 2004</LINK>).</P>
<P>Parenteral Nutrition</P>
<P>
<LINK REF="STD-Layden-1976" TYPE="STUDY">Layden 1976</LINK> and <LINK REF="STD-Strobel-1979" TYPE="STUDY">Strobel 1979</LINK> report 18 cases of improved growth after the introduction of parenteral nutrition for growth failure in Crohn's disease, although no statistical conclusions can be drawn from these data. Parenteral nutrition in the pre-operative period improved post-operative growth for up to a year in 8 children after elective surgery (<LINK REF="STD-Lake-1985" TYPE="STUDY">Lake 1985</LINK>). However the control group were children undergoing emergency surgery for obstruction, so it is difficult to draw any definite conclusions.</P>
<P>Steroids</P>
<P>Studies in other pediatric specialities show growth suppression at dosages equivalent to 4-6 mg/kg of prednisolone per day (<LINK REF="REF-Hyams-1988" TYPE="REFERENCE">Hyams 1988</LINK>). However, as stated earlier sub-optimal disease control may be a much more powerful suppressor of growth than steroid treatment (<LINK REF="STD-Motil-1993" TYPE="STUDY">Motil 1993</LINK>). In this study 65% of 34 children prospectively followed over 3 years received oral prednisolone. When compared with the 35% who did not, there was no significant difference between short and long term measures of growth. Although a tendency to an inverse relationship between length of steroid use and height velocity was noted, this was a weak association (r = -0.16). <LINK REF="REF-Griffiths-1993a" TYPE="REFERENCE">Griffiths 1993a</LINK> retrospectively reviewed growth data on 100 children with Crohn's disease and concluded that, after adjusting for severity of symptoms, steroid administration was not a significant predictor of height velocity. <LINK REF="STD-Kundhal-2001" TYPE="STUDY">Kundhal 2001</LINK> looked at budesonide as an alternative steroid preparation and failed to show any significant benefit for growth in the 32 children studied. A correlation between poor disease control and poor growth was also noted. </P>
<P>Surgery</P>
<P>A number a retrospective reviews appear in the literature concerning the timing of surgery and the beneficial effect of surgery on growth. <LINK REF="STD-Alperstein-1985" TYPE="STUDY">Alperstein 1985</LINK> reviewed the effect of surgery on 26 children with Crohn's disease, of whom 14 were pre-pubertal (i.e. Tanner stage 1, 13 of those having a growth velocity of less than 5 cm/year). Eleven of these 13 children achieved an increase in height velocity after surgery, with 9 showing a height velocity of greater than 5 cm/year. <LINK REF="STD-Davies-1990" TYPE="STUDY">Davies 1990</LINK> noted a similar trend to increased height velocity in the first year after surgery for 40 children with Crohn's disease. These children were older, having a mean age of at least 12.1 years at the time of operation. <LINK REF="STD-McLain-1990" TYPE="STUDY">McLain 1990</LINK> showed increased growth in 19 children after surgical resection, with half of the pubertal children (7/12) also seeing some benefit. <LINK REF="STD-Lipson-1990" TYPE="STUDY">Lipson 1990</LINK> and <LINK REF="REF-Griffiths-1991" TYPE="REFERENCE">Griffiths 1991</LINK> showed good benefit for growth in pre pubertal children.</P>
<P>Infliximab</P>
<P>In the last 5 years infliximab has become a widely accepted treatment for children with severe, refractory Crohn's, especially fistulizing disease. Several studies have reported good efficacy but it's use is not without potential serious adverse effects including anaphylaxis and long-term data are not yet available. One study so far has looked at growth as an outcome measure. <LINK REF="STD-Cezard-2003" TYPE="STUDY">Cezard 2003</LINK> prospectively followed 21 children with severe Crohn's disease. Growth data were reported on the 10 pre-pubertal children within the study group. Height standard deviation scores were recorded 1 year prior the treatment (mean -0.45) and after treatment (mean +0.5; p = 0.004). These results are encouraging, especially in this severely ill group where growth may be more affected. Further studies, with greater numbers of patients, are needed to establish the size of the effect.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Although there are no good quality randomized controlled trials pertaining to growth in childhood Crohn's disease, a body of low quality evidence does exist relevant to two very important interventions; the use of enteral nutrition and the judicious use of surgical interventions in pre pubertal children with refractory disease. Although conflicting evidence exists as to the effectiveness of enteral nutrition compared to corticosteroids for inducing remission, low quality evidence suggests benefit of the nutritional approach in the pediatric population. There is no hard evidence on which to make recommendations for clinical practice.<BR/> </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>This review highlights the need for large, multi centre, randomized controlled trials in this important area of Crohn's disease, using growth as an outcome measure. Of note there are no randomized controlled trials of enteral nutrition versus placebo. A definitive study looking at enteral nutrition versus corticosteroids in pediatric practice would be important. Further trials comparing supplemental nutrition with conventional nutritional advice in steroid treated patients would also be of interest. Where enteral feeds and corticosteroids are used there is great variation in length of treatment courses, type of feed used and dose of corticosteroids because of a lack good quality evidence on which to base practice. Further studies are needed to establish guidelines and to look at the effect of the newer immuno-modulating and biological agents, which are now being used in childhood Crohn's disease. Future trials should employ appropriate assessment of linear growth such as height standard deviation scores and height velocity standard deviation scores.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>AG Thomas is the author of a manuscript that was included in this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Newby EA: Literature search, Critical appraisal of evidence, Author<BR/>Sawczenko A: Design of database for references<BR/>Thomas AG: Critical appraisal of evidence<BR/>Wilson D: Critical appraisal of evidence</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-17 08:59:41 -0400" MODIFIED_BY="John K MacDonald">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Markowitz-2000" NAME="Markowitz 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Markowitz J, Grancher K, Kohn N, Lesser M, Daum F</AU>
<TI>A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>119</VL>
<NO>4</NO>
<PG>895-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanderson-1987" NAME="Sanderson 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sanderson IR, Udeen S, Davies PS, Savage MO, Walker-Smith JA</AU>
<TI>Remission induced by an elemental diet in small bowel Crohn's disease</TI>
<SO>Arch Dis Child</SO>
<YR>1987</YR>
<VL>62</VL>
<NO>2</NO>
<PG>123-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-1993a" NAME="Thomas 1993a" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Thomas AG, Taylor F, Miller V</AU>
<TI>Dietary intake and nutritional treatment in childhood Crohn's disease</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1993</YR>
<VL>17</VL>
<NO>1</NO>
<PG>75-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Akobeng-2000" NAME="Akobeng 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: small amount data on weight only&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Akobeng A, Miller V, Stanton J, Elbadri AM, Thomas AG</AU>
<TI>Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>1</NO>
<PG>78-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akobeng-2002" NAME="Akobeng 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: only 4 week follow-up, unable to comment on growth&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Akobeng AK, Clayton PE, Miller V, Hall CM, Thomas AG</AU>
<TI>Low serum concentrations of insulin-like growth factor-I in children with active Crohn's disease: effect of enteral nutritional support and glutamine supplementation</TI>
<SO>Scand J Gastroenterol</SO>
<YR>2002</YR>
<VL>37</VL>
<NO>12</NO>
<PG>1422-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alperstein-1985" NAME="Alperstein 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: retrospective review&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alperstein G, Daum F, Fisher SE, Aiges H, Markowitz J, Becker J, et al</AU>
<TI>Linear growth following surgery in children and adolescents with Crohn's disease: relationship to pubertal status</TI>
<SO>J Pediatr Surg</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>2</NO>
<PG>129-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baldassano-2003" NAME="Baldassano 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: No height data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, et al</AU>
<TI>Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease</TI>
<SO>Am J Gastroenterol</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>4</NO>
<PG>833-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belli-1988" NAME="Belli 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: cohort series&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Belli DC, Seidman E, Bouthillier L, Weber AM, Roy CC, Pletincx M, et al</AU>
<TI>Chronic intermittent elemental diet improves growth failure in children with Crohn's disease</TI>
<SO>Gastroenterology</SO>
<YR>1988</YR>
<VL>94</VL>
<NO>3</NO>
<PG>603-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campieri-1997" NAME="Campieri 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: adult data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG</AU>
<TI>Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group</TI>
<SO>Gut</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>2</NO>
<PG>209-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cezard-2003" NAME="Cezard 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: Cohort series&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cezard JP, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, et al</AU>
<TI>A prospective study of the efficacy and tolerance of a chimeric antibody to tumour necrosis factors (remicade) in severe pediatric Crohn's disease</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>5</NO>
<PG>632-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-1990" NAME="Davies 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: retrospective review&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davies G, Evans CM, Shand WS, Walker-Smith JA</AU>
<TI>Surgery for Crohn's disease in childhood: influence of disease and operative procedure on outcome</TI>
<SO>Br J Surg</SO>
<YR>1990</YR>
<VL>77</VL>
<NO>8</NO>
<PG>891-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Escher-2004" NAME="Escher 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: No growth data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Escher JC, European Collaborative Research Group on Budesonide in Paediatric IBD</AU>
<TI>Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial</TI>
<SO>Eur J Gastroenterol Hepatol</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>1</NO>
<PG>47-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gassull-2002" NAME="Gassull 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: adult data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gassull MA, Fernandez-Banares F, Cabre E, Papo M, Giaffer MH, Sanchez-Lombrana JL, et al</AU>
<TI>Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial</TI>
<SO>Gut</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>2</NO>
<PG>164-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaya-1999" NAME="Gaya 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: descriptive data only&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gaya DR</AU>
<TI>Crohn's disease in childhood: the case for enteral nutrition</TI>
<SO>Scott Med J</SO>
<YR>1999</YR>
<VL>44</VL>
<NO>3</NO>
<PG>68-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorard-1993" NAME="Gorard 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: adult data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gorard DA, Hunt JB, Payne-James JJ, Palmer KR, Rees RG, Clark ML, et al</AU>
<TI>Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone</TI>
<SO>Gut</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>9</NO>
<PG>1198-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffiths-1993b" NAME="Griffiths 1993b" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: No growth data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Griffths A, Koletzko S, Sylvester F, Marcon M, Sherman P</AU>
<TI>Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1993</YR>
<VL>17</VL>
<NO>2</NO>
<PG>186-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Israel-1995" NAME="Israel 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: Not randomized controllled trial&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Israel DM, Hassall E</AU>
<TI>Prolonged use of gastrostomy for enteral hyperalimentation in children with Crohn's disease</TI>
<SO>Am J Gastroenterol</SO>
<YR>1995</YR>
<VL>90</VL>
<NO>7</NO>
<PG>1084-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khoshoo-1996" NAME="Khoshoo 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: Data on weight only&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Khoshoo V, Reifen R, Neuman MG, Griffiths A, Pencharz PB</AU>
<TI>Effect of low- and high-fat, peptide-based diets on body composition and disease activity in adolescents with active Crohn's disease</TI>
<SO>JPEN J Parenter Enteral Nutr</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>6</NO>
<PG>401-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kugathasan-2000" NAME="Kugathasan 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: no growth data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG</AU>
<TI>Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease</TI>
<SO>Am J Gastroenterol</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>11</NO>
<PG>3189-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kundhal-2001" NAME="Kundhal 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: retrospective data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kundhal P, Zachos M, Holmes JL, Griffiths AM</AU>
<TI>Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>1</NO>
<PG>75-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kundhal-2003" NAME="Kundhal 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: no growth data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kundal PS, Critch JN, Zachos M, Otley AR, Stephens D, Griffiths AM</AU>
<TI>Pediatric Crohn Disease Activity Index: responsive to short-term change</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>1</NO>
<PG>83-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lake-1985" NAME="Lake 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: cohort series&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lake AM, Kim S, Mathis RK, Walker WA</AU>
<TI>Influence of preoperative parenteral alimentation on postoperative growth in adolescent Crohn's disease</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>2</NO>
<PG>182-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Layden-1976" NAME="Layden 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: case report&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Layden T, Rosenberg F, Nemchausky G, Elson C, Rosenberg I</AU>
<TI>Reversal of growth arrest in adolescents with Crohn's disease after parenteral alimentation</TI>
<SO>Gastroenterology</SO>
<YR>1976</YR>
<VL>70</VL>
<NO>6</NO>
<PG>1017-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-2003" NAME="Levine 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: No height data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levine A, Weizman Z, Broide E, Shamir R, Shaoul R, Pacht A, et al</AU>
<TI>A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>2</NO>
<PG>248-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipson-1990" NAME="Lipson 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion : cohort series&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lipson AB, Savage MO, Davies PS, Bassett K, Shand WS, Walker-Smith JA</AU>
<TI>Acceleration of linear growth following intestinal resection for Crohn disease</TI>
<SO>Eur J Pediatr</SO>
<YR>1990</YR>
<VL>149</VL>
<NO>10</NO>
<PG>687-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ludvigsson-2004" NAME="Ludvigsson 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: No height data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ludvigsson JF, Krantz M, Bodin L, Stenhammar L, Lindquist B</AU>
<TI>Elemental verses polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial</TI>
<SO>Acta Paediatr</SO>
<YR>2004</YR>
<VL>93</VL>
<NO>3</NO>
<PG>327-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahdi-1996" NAME="Mahdi 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: no growth data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mahdi G, Israel DM, Hassall E</AU>
<TI>Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children</TI>
<SO>Am J Gastroenterol</SO>
<YR>1996</YR>
<VL>91</VL>
<NO>7</NO>
<PG>1355-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McLain-1990" NAME="McLain 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: retrospective review&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McLain BI, Davidson PM, Stokes KB, Beasley SW</AU>
<TI>Growth after gut resection for Crohn's disease</TI>
<SO>Arch Dis Child</SO>
<YR>1990</YR>
<VL>65</VL>
<NO>7</NO>
<PG>760-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morin-1980" NAME="Morin 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: case report&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morin CL, Roulet M, Roy CC, Weber A</AU>
<TI>Continuous elemental enteral alimentation in children with Crohn's disease and growth failure</TI>
<SO>Gastroenterology</SO>
<YR>1980</YR>
<VL>79</VL>
<NO>6</NO>
<PG>1205-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Motil-1993" NAME="Motil 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: cohort series&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO</AU>
<TI>Growth failure in children with inflammatory bowel disease: a prospective study</TI>
<SO>Gastroenterology</SO>
<YR>1993</YR>
<VL>105</VL>
<NO>3</NO>
<PG>681-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicholls-1994" NAME="Nicholls 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Reason foe exclusion: no growth data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nicholls S, Domizio P, Williams CB, Dawnay A, Braegger CP, MacDonald TT, et al</AU>
<TI>Cyclosporin as initial treatment for Crohn's disease</TI>
<SO>Arch Dis Child</SO>
<YR>1994</YR>
<VL>71</VL>
<NO>3</NO>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papadopoulou-1995" NAME="Papadopoulou 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: not randomized controlled trial&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Papadopoulou A, Rawashdeh MO, Brown GA, McNeish AS, Booth IW</AU>
<TI>Remission following an elemental diet or prednisolone in Crohn's disease</TI>
<SO>Acta Pediatr</SO>
<YR>1995</YR>
<VL>84</VL>
<NO>1</NO>
<PG>79-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polk-1992" NAME="Polk 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: case series&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Polk DB, Hattner JA, Kerner JA Jr</AU>
<TI>Improved growth and disease activity after intermittent administration of a defined formula diet in children with Crohn's disease</TI>
<SO>JPEN J Parenter Enteral Nutr</SO>
<YR>1992</YR>
<VL>16</VL>
<NO>6</NO>
<PG>499-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Royall-1995" NAME="Royall 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: adult data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Royall D, Greenberg GR, Allard JP, Baker JP, Jeejeebhoy KN</AU>
<TI>Total enteral nutrition support improves body composition of patients with active Crohn's disease</TI>
<SO>JPEN J Parenter Enteral Nutr</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>2</NO>
<PG>95-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruuska-1994" NAME="Ruuska 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: Randomized controlled trial but only data on weight.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ruuska T, Savilahti E, Maki M, Ormala T, Visakorpi JK</AU>
<TI>Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>2</NO>
<PG>175-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seidman-1996" NAME="Seidman 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion:abstract only&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Seidman E, Jones A, Issenman R, Griffiths A</AU>
<TI>Relapse prevention/growth enhancement in pediatric Crohn's disease: a multi-centre randomized controlled trial of intermittent enteral nutrition versus alternate day steroids</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>3</NO>
<PG>344</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sentongo-2000" NAME="Sentongo 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: descriptive data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zemel BS</AU>
<TI>Growth, body composition, and nutritional status in children and adolescents with Crohn's disease</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>1</NO>
<PG>33-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stober-1983" NAME="Stober 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: No height data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stober B, Nutzenadel W, Ullrich F</AU>
<TI>Basic diet in Crohn's disease</TI>
<TO>Elementardiat bei Morbus Crohn</TO>
<SO>Monatsschr Kinderheilkd</SO>
<YR>1983</YR>
<VL>131</VL>
<NO>10</NO>
<PG>721-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strobel-1979" NAME="Strobel 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: case series&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Strobel CT, Byrne WJ, Ament ME</AU>
<TI>Home parenteral nutrition in children with Crohn's disease: an effective management alternative</TI>
<SO>Gastrenterology</SO>
<YR>1979</YR>
<VL>77</VL>
<NO>2</NO>
<PG>272-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-1993b" NAME="Thomas 1993b" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: same group of children and growth data as previously included study&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas AG, Holly JM, Taylor F, Miller V</AU>
<TI>Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease</TI>
<SO>Gut</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>7</NO>
<PG>944-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilschanski-1996" NAME="Wilschanski 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: historical cohort study&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wilschanski M, Sherman P, Pencharz P, Davis L, Corey M, Griffiths A</AU>
<TI>Supplementary enteral nutrition maintains remission in paediatric Crohn's disease</TI>
<SO>Gut</SO>
<YR>1996</YR>
<VL>38</VL>
<NO>4</NO>
<PG>543-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zoli-1997" NAME="Zoli 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Reason for exclusion: adult data&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zoli G, Care M, Parazza M, Spano C, Biagi PL, Bernardi M, et al</AU>
<TI>A randomized controlled study comparing elemental diet and steroid treatment in Crohn's disease</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>4</NO>
<PG>735-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-17 08:59:41 -0400" MODIFIED_BY="John K MacDonald">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-17 08:59:41 -0400" MODIFIED_BY="John K MacDonald">
<REFERENCE ID="REF-Akobeng-1999" NAME="Akobeng 1999" TYPE="JOURNAL_ARTICLE">
<AU>Akobeng AK, Suresh-Babu MV, Firth D, Miller V, Mir P, Thomas AG</AU>
<TI>Quality of life in children with Crohn's disease: a pilot study</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>4</NO>
<PG>S37-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Akobeng-2005" MODIFIED="2008-07-17 08:59:41 -0400" MODIFIED_BY="John K MacDonald" NAME="Akobeng 2005" TYPE="COCHRANE_REVIEW">
<AU>Akobeng Ak, Gardener E</AU>
<TI>Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-07-17 08:59:41 -0400" MODIFIED_BY="John K MacDonald">
<IDENTIFIER MODIFIED="2008-07-17 08:59:41 -0400" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="Art. No.: CD003715. DOI: 10.1002/14651858.CD003715.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ballinger-2000" NAME="Ballinger 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ</AU>
<TI>Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis</TI>
<SO>Gut</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>5</NO>
<PG>694-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beattie-1998" NAME="Beattie 1998" TYPE="JOURNAL_ARTICLE">
<AU>Beattie RM, Camacho-Hubner C, Wacharsindhu S, Cotterill AM, Walker-Smith JA, Savage MO</AU>
<TI>Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease</TI>
<SO>Clin Endocrinol (Oxf)</SO>
<YR>1998</YR>
<VL>49</VL>
<NO>4</NO>
<PG>483-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breese-1994" NAME="Breese 1994" TYPE="JOURNAL_ARTICLE">
<AU>Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al</AU>
<TI>Tumour necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease</TI>
<SO>Gastroenterology</SO>
<YR>1994</YR>
<VL>106</VL>
<NO>6</NO>
<PG>1455-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buller-2000" NAME="Buller 2000" TYPE="JOURNAL_ARTICLE">
<AU>Buller HA</AU>
<TI>Growth in children with inflammatory bowel disease</TI>
<SO>Research and Clinical Forums</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>2</NO>
<PG>139-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chafai-1995" NAME="Chafai 1995" TYPE="JOURNAL_ARTICLE">
<AU>Chafai S, Martin D, Goulet O, Mougenot JF, Ricour C, Schmitz J</AU>
<TI>Semi-elemental diet and corticosteroids in the treatment of Crohn's disease in children</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1995</YR>
<VL>220</VL>
<PG>465</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2003" NAME="Clarke 2003" TYPE="BOOK">
<AU>Clarke M, Oxman AD, editors</AU>
<SO>Cochrane Reviewers' Handbook 4.2 [updated March 2003]. In: The Cochrane Library, Issue 4</SO>
<YR>2003</YR>
<PB>Update software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cosgrove-1997" NAME="Cosgrove 1997" TYPE="JOURNAL_ARTICLE">
<AU>Cosgrove M, Jenkins HR</AU>
<TI>Experience of percutaneous endoscopic gastrostomy in children with Crohn's disease</TI>
<SO>Arch Dis Child</SO>
<YR>1997</YR>
<VL>76</VL>
<NO>2</NO>
<PG>141-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Benedetti-1997" NAME="De Benedetti 1997" TYPE="JOURNAL_ARTICLE">
<AU>De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al</AU>
<TI>Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation</TI>
<SO>J Clin Invest</SO>
<YR>1997</YR>
<VL>99</VL>
<NO>4</NO>
<PG>643-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-1991" NAME="Evans 1991" TYPE="JOURNAL_ARTICLE">
<AU>Evans CM, Kirk JM, Savage MO, Walker Smith JA</AU>
<TI>Growth after gut resection for Crohn's disease</TI>
<SO>Arch Dis Child</SO>
<YR>1991</YR>
<VL>66</VL>
<NO>3</NO>
<PG>370</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferguson-1994" NAME="Ferguson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson A, Sedgwick DM</AU>
<TI>Juvenile onset inflammatory bowel disease: height and body mass index in adult life</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<NO>6939</NO>
<PG>1259-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffiths-1991" NAME="Griffiths 1991" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths AM, Wesson DE, Shandling B, Corey M, Sherman PM</AU>
<TI>Factors influencing the postoperative recurrence of Crohn's disease in childhood</TI>
<SO>Gut</SO>
<YR>1991</YR>
<VL>32</VL>
<NO>5</NO>
<PG>491-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffiths-1993a" NAME="Griffiths 1993a" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM</AU>
<TI>Growth and clinical course of children with Crohn's disease</TI>
<SO>Gut</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>7</NO>
<PG>939-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heuschkel--2000" NAME="Heuschkel  2000" TYPE="JOURNAL_ARTICLE">
<AU>Heuschkel R, Menache CC, Megerian JT, Baird AE</AU>
<TI>Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>1</NO>
<PG>8-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hildebrand-1994" NAME="Hildebrand 1994" TYPE="JOURNAL_ARTICLE">
<AU>Hildebrand H, Karlberg J, Kristiansson B</AU>
<TI>Longitudinal growth in children and adolescents with inflammatory bowel disease</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>2</NO>
<PG>165-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hyams-1988" NAME="Hyams 1988" TYPE="JOURNAL_ARTICLE">
<AU>Hyams JS, Carey DE</AU>
<TI>Corticosteroids and growth</TI>
<SO>J Pediatr</SO>
<YR>1988</YR>
<VL>113</VL>
<NO>2</NO>
<PG>249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hyams-1991" NAME="Hyams 1991" TYPE="JOURNAL_ARTICLE">
<AU>Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al</AU>
<TI>Development and validation of a pediatric Crohn's disease activity index</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1991</YR>
<VL>12</VL>
<NO>4</NO>
<PG>439-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hyams-2000" NAME="Hyams 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hyams JS, Markowitz J, Wyllie R</AU>
<TI>Use of infliximab in the treatment of Crohn's disease in children and adolescents</TI>
<SO>J Pediatr</SO>
<YR>2000</YR>
<VL>137</VL>
<NO>2</NO>
<PG>192-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1998" NAME="Jadad 1998" TYPE="BOOK">
<AU>Jadad AR</AU>
<SO>Randomised controlled trials: a user's guide</SO>
<YR>1998</YR>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keller-1992" NAME="Keller 1992" TYPE="JOURNAL_ARTICLE">
<AU>Keller KM, Wirth S</AU>
<TI>Parenteral nutrition in treatment of short stature in adolescents with Crohn disease</TI>
<TO>Parenterale Ernahrung in der Behandlung des Minderwuchses bei Adoleszenten mit Morbus Crohn</TO>
<SO>Klin Padiatr</SO>
<YR>1992</YR>
<VL>204</VL>
<NO>6</NO>
<PG>411-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirschner-1986" NAME="Kirschner 1986" TYPE="JOURNAL_ARTICLE">
<AU>Kirschner BS, Sutton MM</AU>
<TI>Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease</TI>
<SO>Gastroenterology</SO>
<YR>1986</YR>
<VL>91</VL>
<NO>4</NO>
<PG>830-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Markowitz-1993" NAME="Markowitz 1993" TYPE="JOURNAL_ARTICLE">
<AU>Markowitz J, Grancher K, Rosa J, Aiges H, Daum F</AU>
<TI>Growth failure in pediatric inflammatory bowel disease</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>4</NO>
<PG>373-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murch-1991" NAME="Murch 1991" TYPE="JOURNAL_ARTICLE">
<AU>Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT</AU>
<TI>Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease</TI>
<SO>Gut</SO>
<YR>1991</YR>
<VL>32</VL>
<NO>8</NO>
<PG>913-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pearson-1998" MODIFIED="2008-07-17 08:54:42 -0400" MODIFIED_BY="John K MacDonald" NAME="Pearson 1998" TYPE="COCHRANE_REVIEW">
<AU>Pearson DC, May GR, Fick G, Sutherland LR</AU>
<TI>Azathioprine for maintenance of remission in Crohn's disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-07-17 08:54:40 -0400" MODIFIED_BY="John K MacDonald">
<IDENTIFIER MODIFIED="2008-07-17 08:54:40 -0400" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="Art. No.: CD000067. DOI: 10.1002/14651858.CD000067"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Seidman-1991" NAME="Seidman 1991" TYPE="JOURNAL_ARTICLE">
<AU>Seidman EG, Lohoues MJ, Turgeon L, Bouthillier L, Morin CL</AU>
<TI>Elemental diet versus prednisone as initial therapy in Crohn's disease: early and long term results</TI>
<SO>Gastroenterology</SO>
<YR>1991</YR>
<VL>100</VL>
<NO>5 Part 2</NO>
<PG>A250</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seidman-1993" NAME="Seidman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Seidman E, Griffiths AM, Jones A, Issenman R</AU>
<TI>Semi-elemental (S-E) diet vs prednisone in pediatric Crohn's disease</TI>
<SO>Gastroenterology</SO>
<YR>1993</YR>
<VL>104</VL>
<NO>4 Part 2</NO>
<PG>A778</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slonim-2000" NAME="Slonim 2000" TYPE="JOURNAL_ARTICLE">
<AU>Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinlay MJ</AU>
<TI>A preliminary study of growth hormone therapy for Crohn's disease</TI>
<SO>N Engl J Med</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>22</NO>
<PG>1633-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stephens-2003" NAME="Stephens 2003" TYPE="JOURNAL_ARTICLE">
<AU>Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN</AU>
<TI>Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center</TI>
<SO>Am J Gastroenterol</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>1</NO>
<PG>104-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutherland-2006" MODIFIED="2008-07-17 08:56:58 -0400" MODIFIED_BY="John K MacDonald" NAME="Sutherland 2006" TYPE="COCHRANE_REVIEW">
<AU>Sutherland L, MacDonald JK</AU>
<TI>Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-17 08:56:36 -0400" MODIFIED_BY="John K MacDonald">
<IDENTIFIER MODIFIED="2008-07-17 08:56:36 -0400" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="Art. No.: CD000544. DOI: 10.1002/14651858.CD000544.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walker_x002d_Smith-1996" NAME="Walker-Smith 1996" TYPE="JOURNAL_ARTICLE">
<AU>Walker-Smith JA</AU>
<TI>Management of growth failure in Crohn's disease</TI>
<SO>Arch Dis Child</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>4</NO>
<PG>351-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zachos-2007" MODIFIED="2008-07-17 08:53:32 -0400" MODIFIED_BY="John K MacDonald" NAME="Zachos 2007" TYPE="COCHRANE_REVIEW">
<AU>Zachos M, Tondeur M, Griffiths AM</AU>
<TI>Enteral nutritional therapy for induction of remission in Crohn's disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-07-17 08:53:32 -0400" MODIFIED_BY="John K MacDonald">
<IDENTIFIER MODIFIED="2008-07-17 08:53:32 -0400" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="Art. No.: CD000542. DOI: 10.1002/14651858.CD000542.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Markowitz-2000">
<CHAR_METHODS>
<P>Double-blind, randomized, placebo controlled, intention-to-treat basis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>55 children age &lt; 18 years with Crohn's disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>6-mercaptopurine and prednisone verses placebo and prednisone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cumulative prednisone dose, length of remission and linear growth</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sanderson-1987">
<CHAR_METHODS>
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>15 children age &lt; 18 with Crohn's disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Elemental diet verses high dose steroids and sulphasalazine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Height velocity standard deviation score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dose of steroid - 2 IU/kg/day intra-muscular adrenocorticotrophic hormone for 5 days and then prednisolone 2 mg/kg/day (max 30 mg/day), sulphasalazine 50 mg/kg/day</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thomas-1993a">
<CHAR_METHODS>
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24 children age &lt; 18 with Crohn's disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Elemental diet verses prednisolone and sulphasalazine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Height velocity standard deviation score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dose of prednisolone 2 mg/kg/day (max 60 mg/day), tapered after 2 weeks depending on response plus sulphasalazine 25 mg/kg/day</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Akobeng-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Small amount of data pertaining to weight only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Akobeng-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only 4 week follow-up, unable to comment on growth</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alperstein-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baldassano-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data pertaining to height</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Belli-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Campieri-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Adult data only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cezard-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davies-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Escher-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data pertaining to height</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gassull-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Adult data only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gaya-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Descriptive data only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gorard-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Adult data only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Griffiths-1993b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data pertaining to height</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Israel-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Khoshoo-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data on weight only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kugathasan-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No growth data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kundhal-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kundhal-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No growth data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lake-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Layden-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levine-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data pertaining to height</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipson-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ludvigsson-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data pertaining to height</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahdi-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No growth data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McLain-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morin-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case reports</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Motil-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nicholls-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No growth data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Papadopoulou-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Polk-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Royall-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Adult data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ruuska-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data on weight only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seidman-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sentongo-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Descriptive data only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stober-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data pertaining to height</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Strobel-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thomas-1993b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Same data as included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilschanski-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case control study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zoli-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Adult data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Markowitz-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sanderson-1987">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Thomas-1993a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>6-mercaptopurine versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.6416776444237744" CI_START="-0.6416776444237744" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.16983617958018563" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="1.37273038473588">
<NAME>Linear growth</NAME>
<GROUP_LABEL_1>6-mercaptopurine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MP</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.6416776444237744" CI_START="-0.6416776444237744" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="5.3" ORDER="27731" SD_1="4.1" SD_2="4.0" SE="1.0927127545797037" STUDY_ID="STD-Markowitz-2000" TOTAL_1="27" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Elemental feed versus prednisolone</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="19" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Height velocity standard deviation scores</NAME>
<GROUP_LABEL_1>Elemental feed</GROUP_LABEL_1>
<GROUP_LABEL_2>Prednisolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prednisolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours elemental</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.425652038423445" CI_START="0.7743479615765541" EFFECT_SIZE="3.0999999999999996" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-2.8" ORDER="27732" SD_1="2.03" SD_2="2.5" SE="1.1865789661278943" STUDY_ID="STD-Sanderson-1987" TOTAL_1="8" TOTAL_2="7" WEIGHT="0.0"/>
<CONT_DATA CI_END="5.877287340060526" CI_START="0.9627126599394731" EFFECT_SIZE="3.42" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="-3.1" ORDER="27733" SD_1="3.32" SD_2="2.8" SE="1.253741068429469" STUDY_ID="STD-Thomas-1993a" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>